The Experts below are selected from a list of 264 Experts worldwide ranked by ideXlab platform
K Ramaesh - One of the best experts on this subject based on the ideXlab platform.
-
Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients
Eye, 2009Co-Authors: K Spiteri Cornish, S Ramamurthi, S Saidkasimova, K RamaeshAbstract:Purpose To report two cases of young diabetic patients with intractable neovascular glaucoma (NVG) who were successfully managed with bevacizumab and mitomycin C-augmented trabeculectomy. Results Two young patients present with severe NVG secondary to diabetic proliferative retinopathy. The glaucoma was unresponsive to conventional medical therapy and complete panretinal photocoagulation. Both patients underwent augmented trabeculectomy with MMC and intravitreal injection of bevacizumab. Iris Rubeosis resolved within 48 h. Both patients have a follow-up period of 6 months and the intraocular pressure (IOP) remain between 10–15 mmHg. Conclusions Controlling IOP due to NVG in young diabetic patients is difficult and augmented trabeculectomy has a very high failure rate. The addition of intravitreal bevacizumab in the management of NVG particularly in young diabetic patients may improve the success rate of IOP control. It is known that bevacizumab retards neovascularisation. It may also be modulating wound-healing response as well. Bevacizumab may have a potential role in the surgical management of NVG.
-
Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients.
Eye, 2008Co-Authors: K Spiteri Cornish, S Ramamurthi, S Saidkasimova, K RamaeshAbstract:To report two cases of young diabetic patients with intractable neovascular glaucoma (NVG) who were successfully managed with bevacizumab and mitomycin C-augmented trabeculectomy. Two young patients present with severe NVG secondary to diabetic proliferative retinopathy. The glaucoma was unresponsive to conventional medical therapy and complete panretinal photocoagulation. Both patients underwent augmented trabeculectomy with MMC and intravitreal injection of bevacizumab. Iris Rubeosis resolved within 48 h. Both patients have a follow-up period of 6 months and the intraocular pressure (IOP) remain between 10–15 mmHg. Controlling IOP due to NVG in young diabetic patients is difficult and augmented trabeculectomy has a very high failure rate. The addition of intravitreal bevacizumab in the management of NVG particularly in young diabetic patients may improve the success rate of IOP control. It is known that bevacizumab retards neovascularisation. It may also be modulating wound-healing response as well. Bevacizumab may have a potential role in the surgical management of NVG.
Michael H. Foerster - One of the best experts on this subject based on the ideXlab platform.
-
Rubeosis iridis after vitrectomy for diabetic retinopathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 1998Co-Authors: Horst Helbig, Ulrich Kellner, Norbert Bornfeld, Michael H. FoersterAbstract:· Background: Iris Rubeosis and neovascular glaucoma (NVG) are serious complications of vitrectomy for proliferative diabetic retinopathy. The present study analyzes incidence and risk factors of these complications. · Methods: Preoperative and postoperative Iris Rubeosis were compared in 389 diabetic eyes after vitrectomy. Minimum follow-up was 6 months (median 26 months). Risk factors were studied using multivariate logistic regression analysis. · Results: Following vitrectomy, in 8.5% of the eyes stromal Iris Rubeosis developed de novo; NVG occurred in 5%. Significant risk factors for postoperative Rubeosis were preexisting Iris neovascularizations and postoperative retinal detachment. Six months after surgery, regression of preexisting Iris Rubeosis was observed in 57% of the eyes. In eyes without preoperative Iris Rubeosis, progression was found in 13% of cases 6 months postoperatively. · Conclusion: With current surgical techniques Iris Rubeosis is more commonly regressive than progressive after vitreous surgery in diabetic eyes.
-
Vitrektomie bei diabetischer Retinopathie: Ergebnisse, Risikofaktoren, Komplikationen
Klinische Monatsblätter für Augenheilkunde, 1998Co-Authors: Horst Helbig, Ulrich Kellner, Norbert Bornfeld, Michael H. FoersterAbstract:BACKGROUND Functional results, risk factors and complications of vitrectomy for diabetic retinopathy were studied to improve our estimation for benefits and risks of vitreous surgery with current techniques. MATERIALS AND METHODS The course of 389 consecutive eyes, who had undergone vitreous surgery for complications of diabetic retinopathy within a four year period, was retrospectively reviewed. The minimum follow-up was 6 months, the median 26 months. Risk factors were studied using multivariate logistic regression analysis. RESULTS Six months postoperatively 25% of the eyes had a visual acuity of 20/60 or better, a vision of less than 5/200 was found in 25% of the eyes. The most important risk factors were detachment of the macula and Iris Rubeosis. Only 16% of the eyes with tractional detachment of the macula had a postoperative vision of 20/200 or better, although in 86% the macula was anatomically successfully reattached. Postoperative retinal detachment was observed in 18% of all eyes. The incidence of this serious complication was only 5% after surgery for vitreous hemorrhage, but 54% after vitrectomy for tractional detachment of the macula. CONCLUSIONS In eyes with advanced stages of long-standing tractional detachment of the macula, the functional prognosis is very poor due to the underlying microvascular disease. In less advanced stages with vitreous hemorrhage and flat retina the risk of vitreous surgery is low.
K Spiteri Cornish - One of the best experts on this subject based on the ideXlab platform.
-
Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients
Eye, 2009Co-Authors: K Spiteri Cornish, S Ramamurthi, S Saidkasimova, K RamaeshAbstract:Purpose To report two cases of young diabetic patients with intractable neovascular glaucoma (NVG) who were successfully managed with bevacizumab and mitomycin C-augmented trabeculectomy. Results Two young patients present with severe NVG secondary to diabetic proliferative retinopathy. The glaucoma was unresponsive to conventional medical therapy and complete panretinal photocoagulation. Both patients underwent augmented trabeculectomy with MMC and intravitreal injection of bevacizumab. Iris Rubeosis resolved within 48 h. Both patients have a follow-up period of 6 months and the intraocular pressure (IOP) remain between 10–15 mmHg. Conclusions Controlling IOP due to NVG in young diabetic patients is difficult and augmented trabeculectomy has a very high failure rate. The addition of intravitreal bevacizumab in the management of NVG particularly in young diabetic patients may improve the success rate of IOP control. It is known that bevacizumab retards neovascularisation. It may also be modulating wound-healing response as well. Bevacizumab may have a potential role in the surgical management of NVG.
-
Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients.
Eye, 2008Co-Authors: K Spiteri Cornish, S Ramamurthi, S Saidkasimova, K RamaeshAbstract:To report two cases of young diabetic patients with intractable neovascular glaucoma (NVG) who were successfully managed with bevacizumab and mitomycin C-augmented trabeculectomy. Two young patients present with severe NVG secondary to diabetic proliferative retinopathy. The glaucoma was unresponsive to conventional medical therapy and complete panretinal photocoagulation. Both patients underwent augmented trabeculectomy with MMC and intravitreal injection of bevacizumab. Iris Rubeosis resolved within 48 h. Both patients have a follow-up period of 6 months and the intraocular pressure (IOP) remain between 10–15 mmHg. Controlling IOP due to NVG in young diabetic patients is difficult and augmented trabeculectomy has a very high failure rate. The addition of intravitreal bevacizumab in the management of NVG particularly in young diabetic patients may improve the success rate of IOP control. It is known that bevacizumab retards neovascularisation. It may also be modulating wound-healing response as well. Bevacizumab may have a potential role in the surgical management of NVG.
Salvatore Grisanti - One of the best experts on this subject based on the ideXlab platform.
-
Ranibizumab as adjuvant in the treatment of Rubeosis iridis and neovascular glaucoma—results from a prospective interventional case series
Graefe's Archive for Clinical and Experimental Ophthalmology, 2013Co-Authors: Julia Lüke, Khaled Nassar, Matthias Lüke, Salvatore GrisantiAbstract:Background To evaluate the capability of adjuvant intraocular ranibizumab (Lucentis®) injections in the treatment of Rubeosis and intraocular pressure in patients with Rubeosis and neovascular glaucoma. Methods Ten eyes with Rubeosis (R) and ten eyes with neovascular glaucoma (NVG) received Lucentis® injections (ranibizumab 0.5 mg/0.05 ml) in this prospective, monocenter, 12-months, interventional case series. The primary efficacy outcome measure was the change of degree of Iris Rubeosis as documented by Iris fluorescein angiography measured after 12 months. Secondary outcomes were intraocular pressure (IOP), best-corrected visual acuity (BCVA, logMAR), numbers of additional interventions or antiglaucoma medications administered after injection, the gonioscopic status of the anterior chamber angle, and central retinal thickness. Results In the R group, 3.6 injections and in the NVG group 2.3 injections of Lucentis® were administered. Additional treatments were photocoagulation ( n = 19), cyclodestructive procedures ( n = 9), cryopexy ( n = 3), and vitrectomy ( n = 1). The mean stage of Rubeosis was 3.4 ± 0.7 in the R group and 3.6 ± 0.8 in the NVG group at baseline. At month 12, the Rubeosis was almost resolved in the R group (0.1 ± 0.3, p
-
Bevacizumab as adjuvant for neovascular glaucoma
Acta Ophthalmologica, 2010Co-Authors: Julia Beutel, Swaantje Peters, Matthias Lüke, Sabin Aisenbrey, Peter Szurman, Martin S. Spitzer, Efdal Yoeruek, Salvatore GrisantiAbstract:. Purpose: We aimed to evaluate the longterm effects of intraocular bevacizumab (Avastin®) injections as adjuvant treatment in patients with neovascular glaucoma. Methods: Twenty eyes of 18 consecutive patients with secondary neovascular glaucoma caused by proliferative diabetic retinopathy (n = 7), ischaemic central retinal vein occlusion (n = 7), ischaemic ophthalmopathy (n = 2) and retinal ischaemia resulting from persistent detachment (n = 2) were treated with intraocular bevacizumab injections (1.25 mg/0.05 ml) in addition to other treatments. The main outcome measure was the change in degree of Iris Rubeosis. Secondary outcomes included intraocular pressure (IOP), best corrected visual acuity (BCVA) and numbers of additional interventions or antiglaucoma medications administered after injection. Results: Mean (± standard deviation) follow-up was 67.7 ± 13.8 weeks (range 50–93 weeks). At the last follow-up, complete regression of Rubeosis was detectable in five (20%) eyes, incomplete regression in seven (35%), stabilization in six (30%), and an increase in two (10%) eyes. Mean IOP was 26.0 ± 8.9 mmHg at baseline and significantly decreased to 14.75 ± 5.3 mmHg at the last follow-up visit (p = 0.000005). Mean baseline BCVA (logMAR [logarithm of the minimum angle of resolution] 1.43 ± 0.89) was stabilized during the follow-up period (logMAR 1.5 ± 0.98). Patients received an average of 2.75 injections. Additional treatments were laser photocoagulation in 13 (65%) eyes, cyclodestructive procedure in 14 (70%), cryopexy in six (30%), drainage procedures in two (10%), and vitrectomy in five (25%) eyes. Conclusions: Bevacizumab may be beneficial as adjuvant treatment in neovascular glaucoma because of its anti-angiogenic properties and its ability to prevent establishment or progression of angular obstruction. The causative disease inducing the angiogenic process requires treatment in all cases. Antiglaucoma treatment is needed in cases of persistent elevated IOP.
-
Intracameral Bevacizumab for Iris Rubeosis
American Journal of Ophthalmology, 2006Co-Authors: Salvatore Grisanti, Sabine Biester, Swaantje Peters, O. Tatar, Focke Ziemssen, Karl Ulrich Bartz-schmidtAbstract:Purpose To determine whether intracameral bevacizumab decreases vascular leakage from Iris Rubeosis in patients with neovascular glaucoma. Design Interventional case series. Methods The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by Iris fluorescein angiography. Results Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Conclusion Intraocular injection of bevacizumab may provide an additional strategy for the treatment of Iris Rubeosis in neovascular glaucoma.
Horst Helbig - One of the best experts on this subject based on the ideXlab platform.
-
Rubeosis iridis after vitrectomy for diabetic retinopathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 1998Co-Authors: Horst Helbig, Ulrich Kellner, Norbert Bornfeld, Michael H. FoersterAbstract:· Background: Iris Rubeosis and neovascular glaucoma (NVG) are serious complications of vitrectomy for proliferative diabetic retinopathy. The present study analyzes incidence and risk factors of these complications. · Methods: Preoperative and postoperative Iris Rubeosis were compared in 389 diabetic eyes after vitrectomy. Minimum follow-up was 6 months (median 26 months). Risk factors were studied using multivariate logistic regression analysis. · Results: Following vitrectomy, in 8.5% of the eyes stromal Iris Rubeosis developed de novo; NVG occurred in 5%. Significant risk factors for postoperative Rubeosis were preexisting Iris neovascularizations and postoperative retinal detachment. Six months after surgery, regression of preexisting Iris Rubeosis was observed in 57% of the eyes. In eyes without preoperative Iris Rubeosis, progression was found in 13% of cases 6 months postoperatively. · Conclusion: With current surgical techniques Iris Rubeosis is more commonly regressive than progressive after vitreous surgery in diabetic eyes.
-
Vitrektomie bei diabetischer Retinopathie: Ergebnisse, Risikofaktoren, Komplikationen
Klinische Monatsblätter für Augenheilkunde, 1998Co-Authors: Horst Helbig, Ulrich Kellner, Norbert Bornfeld, Michael H. FoersterAbstract:BACKGROUND Functional results, risk factors and complications of vitrectomy for diabetic retinopathy were studied to improve our estimation for benefits and risks of vitreous surgery with current techniques. MATERIALS AND METHODS The course of 389 consecutive eyes, who had undergone vitreous surgery for complications of diabetic retinopathy within a four year period, was retrospectively reviewed. The minimum follow-up was 6 months, the median 26 months. Risk factors were studied using multivariate logistic regression analysis. RESULTS Six months postoperatively 25% of the eyes had a visual acuity of 20/60 or better, a vision of less than 5/200 was found in 25% of the eyes. The most important risk factors were detachment of the macula and Iris Rubeosis. Only 16% of the eyes with tractional detachment of the macula had a postoperative vision of 20/200 or better, although in 86% the macula was anatomically successfully reattached. Postoperative retinal detachment was observed in 18% of all eyes. The incidence of this serious complication was only 5% after surgery for vitreous hemorrhage, but 54% after vitrectomy for tractional detachment of the macula. CONCLUSIONS In eyes with advanced stages of long-standing tractional detachment of the macula, the functional prognosis is very poor due to the underlying microvascular disease. In less advanced stages with vitreous hemorrhage and flat retina the risk of vitreous surgery is low.
